LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

LLY

1,020.69

-0.81%↓

JNJ

243.4

-0.72%↓

ABBV

224.52

-1.08%↓

NVS

165.19

-0.73%↓

MRK

119.22

-2.61%↓

Search

Champions Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.82 1.04

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.76

Max

5.97

Pagrindiniai rodikliai

By Trading Economics

Pajamos

702K

236K

Pardavimai

1M

15M

P/E

Sektoriaus vid.

34.412

108.767

Pelno marža

1.57

Darbuotojai

213

EBITDA

1.1M

612K

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+100.67% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-10

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-26M

81M

Ankstesnė atidarymo kaina

4.78

Ankstesnė uždarymo kaina

5.82

Naujienos nuotaikos

By Acuity

50%

50%

168 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Champions Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-26 22:04; UTC

Uždarbis

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

2026-02-26 23:55; UTC

Rinkos pokalbiai

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

2026-02-26 23:40; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

2026-02-26 23:37; UTC

Rinkos pokalbiai

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

2026-02-26 23:32; UTC

Uždarbis

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

2026-02-26 23:19; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026-02-26 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

2026-02-26 23:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-02-26 23:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Gives Up in Bidding War Over Warner -- Market Talk

2026-02-26 23:01; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026-02-26 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

2026-02-26 22:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-26 22:43; UTC

Rinkos pokalbiai

RBA Hike In March Is Being Underpriced -- Market Talk

2026-02-26 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026-02-26 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

2026-02-26 22:13; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Bidding War Over Warner Bros. Set to Continue -- Market Talk

2026-02-26 21:59; UTC

Uždarbis

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

2026-02-26 21:58; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

2026-02-26 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-26 21:49; UTC

Uždarbis

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

2026-02-26 21:45; UTC

Uždarbis

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

2026-02-26 21:44; UTC

Uždarbis

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

2026-02-26 21:44; UTC

Uždarbis

Coles Expects Market to Remain Highly Competitive

2026-02-26 21:44; UTC

Uždarbis

Coles Says Supermarket Customers Remain Value Oriented

2026-02-26 21:43; UTC

Uždarbis

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

2026-02-26 21:43; UTC

Uždarbis

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

2026-02-26 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

2026-02-26 21:41; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Champions Oncology Inc Prognozė

Kainos tikslas

By TipRanks

100.67% į viršų

12 mėnesių prognozė

Vidutinis 12 USD  100.67%

Aukščiausias 12 USD

Žemiausias 12 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Champions Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.77 / 7.61Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Strong Bearish Evidence

Rinkos nuotaikos

By Acuity

168 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
help-icon Live chat